A paclitaxel-carboplatin (PCb) regimen may be an alternative adjuvant chemotherapeutic strategy for women with operable triple-negative breast cancer (TNBC), given its greater benefit over a conventional regimen comprising cyclophosphamide, epirubicin, and fluorouracil, followed by docetaxel (CEF-T), the phase III PATTERN* trial has shown.
A blood serum microRNA biomarker signature for oropharyngeal squamous cell carcinoma was recently reported in the Journal of Translational Medicine.The researchers involved in its discovery are expanding on this finding to develop a blood test model that will help predict or diagnose head and neck cancers. [Available at https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02446-1 Accessed on 14 September 2020]
The PD-1 inhibitor nivolumab continues to yield sustained recurrence-free survival (RFS) benefit over ipilimumab with better tolerability at 4 years in the adjuvant setting for patients with resected stage IIIB–C or IV melanoma, according to the CheckMate238 trial presented at ESMO 2020.
For patients with unresectable malignant pleural mesothelioma (MPM), nivolumab plus ipilimumab in the first-line setting demonstrated greater overall survival (OS) than standard-of-care (SoC) platinum chemotherapy, interim analysis of the phase III CheckMate743 trial revealed.
The addition of venetoclax to azacitidine improved survival and remission rates in previously untreated adults with acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy (CT), the VIALE-A trial has shown.
Breast cancer screening and the optimal age for offering mammography remain matters of debate. A randomized, controlled trial in over 150,000 women in the UK has found that yearly mammography before the age of 50 years, commencing at 40 or 41 years of age, is associated with a relative reduction in breast cancer mortality.
Combining the anti-PD-1 antibody sintilimab with a pemetrexed-platinum chemotherapy regimen improved survival outcomes in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC), interim analysis of the phase III ORIENT-11* trial from China showed.
Tobacco smoking exposure appears to result in lower neoadjuvant chemotherapy response rates as well as higher overall and cancer-specific mortality, according to a systematic review and meta-analysis. Smoking status is also associated with bladder cancer recurrence after radical cystectomy.
In individuals undergoing definitive chemoradiotherapy (CRT) for head and neck squamous cell carcinoma (HNSCC), the use of NSAIDs was associated with a significantly better overall survival (OS), a study has shown.
Drawing from experience as a key investigator in landmark
clinical trials (including PALOMA, MONALEESA and
MONARCH), and his clinical experience with
CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his
insights into the current evidence of using CDK4/6 inhibitors
to treat HR+/HER2- ABC.